Glenmark USA launches Lacosamide Oral Solution, 10 mg/mL

According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million

Strides receives USFDA approval for Levetiracetam Oral Solution

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.

Rystiggo needs marketing strategy to fully compete in myasthenia gravis space, says GlobalData

Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024

Granules India receives ANDA approval for Levetiracetam Tablets

Granules now has a total of 58 ANDA approvals from US FDA

Lupin receives USFDA approval for Brivaracetam Tablets

GlycoEra AG appoints Tanmoy Ganguly as Chief Scientific Officer

Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics

Jonathan Peacock elected Chairman of the Board of Directors of Avantor

Peacock also serves as a Director and Chair of the Audit and Finance Committee of UCB SA, a biopharmaceutical company focusing on neurology and immunology

Indoco Remedies receives USFDA approval for Lacosamide tablets

According to IQVIA sales data for the period ending January 2022, Vimpat tablets market achieved annual sales of approx. US $ 1.7 billion

Glenmark receives ANDA approval for Lacosamide tablets

The company plans to launch the product immediately

Alembic Pharmaceuticals receives USFDA approval for Lacosamide tablets

The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older